Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gut Microbiome Intervention With EXL01 in Combination With Nivolumab and FOLFOX as First-line Treatment for Patients With PD-L1 CPS ≥5 Metastatic Gastric Cancer: A Randomized GERCOR Phase II Study (BIG)

NCT06253611 is registered in ClinicalTrials.gov with GERCOR - Multidisciplinary Oncology Cooperative Group as lead sponsor.

NCT NCT06253611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06253611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gut Microbiome Intervention With EXL01 in Combination With Nivolumab and FOLFOX as First-line Treatment for Patients With PD-L1 CPS ≥5 Metastatic Gastric Cancer: A Randomized GERCOR Phase II Study (BIG)
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase
Phase 2
Overall status
Recruiting
Start date
April 16, 2024
Completion date
April 30, 2029
Enrollment
120 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer